Errol de Souza
Chairman chez CYCLERION THERAPEUTICS, INC.
Fortune : 34 M $ au 31/03/2024
Profil
Errol B.
de Souza founded Neurocrine Biosciences, Inc. in 1992, where he worked as Director, Executive VP-Research & Development from 1992 to 1998.
Dr. de Souza also currently works at Cyclerion Therapeutics, Inc., as Chairman, nLife Therapeutics SL, as President & Director, Kures, Inc., as Director, Royalty Pharma Plc, as Independent Director from 2020, and Alector, Inc., as Director from 2024.
Dr. de Souza also formerly worked at Lundbeck Research USA, Inc., as President, Chief Executive Officer & Director from 2002 to 2003, Archemix Corp., as President, Chief Executive Officer & Director from 2003 to 2009, Biodel, Inc., as President, Chief Executive Officer & Director from 2011 to 2016, Neuropore Therapies, Inc., as President, Chief Executive Officer & Director from 2017 to 2019, Albireo Pharma, Inc., as President & Chief Executive Officer, Merial, Inc., as Chairman-Technology Committee, IDEXX Laboratories, Inc., as Director from 2003 to 2009, Palatin Technologies, Inc., as Director from 2003 to 2010, Bionomics Ltd., as Non-Executive Director in 2023, Targacept, Inc., as Independent Director from 2011 to 2015, Catalyst Biosciences, Inc., as Independent Director from 2015 to 2022, Aventis Pharmaceuticals, Inc., as Senior VP, Head-US Research & Development from 1998 to 2002, DuPont Merck Pharmaceutical Co., as Head-CNS Diseases Research from 1990 to 1992, and Hoechst Marion Roussel, Inc., as Senior VP, Head-US Research & Development from 1998 to 2002.
Dr. de Souza received his undergraduate degree and doctorate degree from the University of Toronto.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RPI US Partners 2019 LP
0,25% | 16/06/2020 | 539 150 ( 0,25% ) | 16 M $ | 31/03/2024 |
| 11/04/2023 | 500 140 ( 0,21% ) | 15 M $ | 31/03/2024 | |
| 23/06/2023 | 64 445 ( 0,01% ) | 2 M $ | 31/03/2024 | |
ALECTOR, INC.
0,04% | 19/03/2024 | 41 250 ( 0,04% ) | 248 325 $ | 31/03/2024 |
| 30/11/2023 | 30 000 ( 1,11% ) | 96 000 $ | 31/03/2024 |
Postes actifs de Errol de Souza
| Sociétés | Poste | Début |
|---|---|---|
| ROYALTY PHARMA PLC | Director/Board Member | 01/06/2020 |
| CYCLERION THERAPEUTICS, INC. | Chairman | - |
| ALECTOR, INC. | Director/Board Member | 19/03/2024 |
Kures, Inc.
 Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | Director/Board Member | - |
nLife Therapeutics SL
 nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain. | President | - |
Anciens postes connus de Errol de Souza
| Sociétés | Poste | Fin |
|---|---|---|
| BIONOMICS LIMITED | Chairman | 01/07/2023 |
| CATALYST BIOSCIENCES | Director/Board Member | 26/12/2022 |
Neuropore Therapies, Inc.
 Neuropore Therapies, Inc. Medical/Nursing ServicesHealth Services Neuropore Therapies, Inc. provides biopharmaceutical services. It also offers alpha-synuclein (ASYN), amyloid beta, autophagy, and publications programs. The company was founded by Eliezer Masliah in 2008 and is headquartered in San Diego, CA. | Chief Executive Officer | 01/12/2019 |
Biodel, Inc.
 Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | Chief Executive Officer | 26/01/2016 |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Errol de Souza
| University of Toronto | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| IDEXX LABORATORIES, INC. | Health Technology |
| NEUROCRINE BIOSCIENCES, INC. | Health Technology |
| PALATIN TECHNOLOGIES, INC. | Health Technology |
| BIONOMICS LIMITED | Health Technology |
| ALECTOR, INC. | Health Technology |
| CYCLERION THERAPEUTICS, INC. | Health Technology |
| ROYALTY PHARMA PLC | Health Technology |
| Entreprise privées | 13 |
|---|---|
Lundbeck Research USA, Inc.
 Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Health Technology |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Commercial Services |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Health Technology |
Merial, Inc.
 Merial, Inc. Pharmaceuticals: MajorHealth Technology Merial, Inc. develops pharmaceutical products and vaccines for pets and wildlife. It provides healthcare products and food for dogs, cats, cattle, horse, and poultry producers. The company was founded in August 1997 and is headquartered in Duluth, GA. | Health Technology |
| Hoechst Marion Roussel, Inc. | |
nLife Therapeutics SL
nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain. | Health Technology |
Neuropore Therapies, Inc.
Neuropore Therapies, Inc. Medical/Nursing ServicesHealth Services Neuropore Therapies, Inc. provides biopharmaceutical services. It also offers alpha-synuclein (ASYN), amyloid beta, autophagy, and publications programs. The company was founded by Eliezer Masliah in 2008 and is headquartered in San Diego, CA. | Health Services |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | Health Technology |
